Product Name | Tafluprost |
CAS NO | 209860-87-7 |
Appearance | White powder |
MF | C25H34F2O5 |
MW | 452.53 |
Usage | Used to reduce intraocular pressure in patients with primary open-angle glaucoma or high intraocular pressure. |
Purity | 99%min |
Origin | China |
Export market | Global |
Grade | Pharmaceutical grade |
Supply capacity | Mass in stock |
Packing | Well disguised package to pass the customs |
Payment | Western Union, Money Gram, Bank Transfer |
Shipping | EMS,HKEMS,FEDEX,DHL,TNT,Aramex,etc |
Leading time | Within 24 hours after payment. |
Delivery time | 3-7 work days |
99% passing rate & 100% free resend policy |
Tafluprost (trade names Taflotan by Santen Pharmaceutical and Zioptan by Merck in the US) is a prostaglandin analogue. It is used topically (as eye drops) to control the progression of open-angle glaucoma and in the management of ocular hypertension, alone or in combination with other medication. It reduces intraocular pressure by increasing the outflow of aqueous fluid from the eyes.
The most common side effect is conjunctival hyperemia, which occurs in 4 to 20% of patients. Less common side effects include stinging of the eyes, headache, and respiratory infections. Rare side effects are dyspnoea (breathing difficulties), worsening of asthma, and macular oedema.
Nonsteroidal anti-inflammatory drugs (NSAIDs) can either reduce or increase the effect of tafluprost. Timolol eye drops, a common kind of glaucoma medication, does not negatively interact with this drug.
Tafluprost, as a lipophilic ester, easily penetrates the cornea and is then activated to the carboxylic acid, tafluprost acid. Onset of action is 2 to 4 hours after application, the maximal effect is reached after 12 hours, and ocular pressure remains lowered for at least 24 hours.
Tafluprost acid is inactivated by beta oxidation to 1,2-dinortafluprost acid, 1,2,3,4-tetranortafluprost acid, and its lactone, which are subsequently glucuronidated or hydroxylated. The cytochrome P450 liver enzymes play no role in the metabolism.
An analogous pathway (at least up to the tetranor-metabolites) has been found for latanoprost and travoprost.